Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled seladelpar study in primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid
2018-001171-20Phase 3Suspended
- Sponsor
- CymaBay Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of seladelpar in primary biliary cholangitis (PBC) (3 arms), sponsored by CymaBay Therapeutics. Primary endpoint: Response on the composite endpoint of alkaline phosphatase and total bilirubin at 12 months. Started Oct 2018; status: suspended.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2018-001171-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001171-20.